Drugs / CART-TnMUC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04025216 | Oct 2019 → Dec 2022 | fallopian tube cancer, non-small cell lung carcinoma, ovarian cancer, pancreatic ductal adenocarcinoma +2 | Kite, A Gilead Company | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-TnMUC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04025216 ↗ |
| Modality | Cell therapy | “genetically modified autologous T cells” NCT04025216 ↗ |
| Route | Intravenous | “Single intravenous administration” NCT04025216 ↗ |